SILVERBACK THERAPEUTICS INC (SBTX) Fundamental Analysis & Valuation

NASDAQ:SBTX • US82835W1080

Current stock price

5.87 USD
+0.06 (+1.03%)
Last:

This SBTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SBTX Profitability Analysis

1.1 Basic Checks

  • SBTX had negative earnings in the past year.
  • SBTX had a negative operating cash flow in the past year.
SBTX Yearly Net Income VS EBIT VS OCF VS FCFSBTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 -20M -40M -60M -80M

1.2 Ratios

Industry RankSector Rank
ROA -31.5%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SBTX Yearly ROA, ROE, ROICSBTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 0 200 -200 400

1.3 Margins

  • SBTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SBTX Yearly Profit, Operating, Gross MarginsSBTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. SBTX Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, SBTX has more shares outstanding
  • SBTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SBTX Yearly Shares OutstandingSBTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 10M 20M 30M
SBTX Yearly Total Debt VS Total AssetsSBTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 100M 200M 300M

2.2 Solvency

  • SBTX has an Altman-Z score of 30.54. This indicates that SBTX is financially healthy and has little risk of bankruptcy at the moment.
  • SBTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 30.54
ROIC/WACCN/A
WACCN/A
SBTX Yearly LT Debt VS Equity VS FCFSBTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 0 100M 200M 300M

2.3 Liquidity

  • SBTX has a Current Ratio of 67.87. This indicates that SBTX is financially healthy and has no problem in meeting its short term obligations.
  • SBTX has a Quick Ratio of 67.87. This indicates that SBTX is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 67.87
Quick Ratio 67.87
SBTX Yearly Current Assets VS Current LiabilitesSBTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. SBTX Growth Analysis

3.1 Past

  • SBTX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.10%.
EPS 1Y (TTM)-6.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, SBTX will show a small growth in Earnings Per Share. The EPS will grow by 5.17% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y26.29%
EPS Next 2Y8.78%
EPS Next 3Y4.57%
EPS Next 5Y5.17%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SBTX Yearly EPS VS EstimatesSBTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5 -2 -2.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. SBTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SBTX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SBTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SBTX Price Earnings VS Forward Price EarningsSBTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.42
SBTX Per share dataSBTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.78%
EPS Next 3Y4.57%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SBTX Dividend Analysis

5.1 Amount

  • No dividends for SBTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

SBTX Fundamentals: All Metrics, Ratios and Statistics

SILVERBACK THERAPEUTICS INC

NASDAQ:SBTX (11/8/2022, 4:30:02 PM)

5.87

+0.06 (+1.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11
Earnings (Next)11-22
Inst Owners179.25%
Inst Owner Change4.2%
Ins Owners3.19%
Ins Owner Change0%
Market Cap210.63M
Revenue(TTM)N/A
Net Income(TTM)-85.38M
Analysts43.33
Price Target5.1 (-13.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.56%
Min EPS beat(2)-11.56%
Max EPS beat(2)-11.56%
EPS beat(4)1
Avg EPS beat(4)-11.06%
Min EPS beat(4)-28.04%
Max EPS beat(4)6.43%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.79
P/tB 0.79
EV/EBITDA 1.42
EPS(TTM)-2.56
EYN/A
EPS(NY)-2.09
Fwd EYN/A
FCF(TTM)-2.06
FCFYN/A
OCF(TTM)-2.03
OCFYN/A
SpS0
BVpS7.44
TBVpS7.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.5%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 171.39%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 67.87
Quick Ratio 67.87
Altman-Z 30.54
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)112.5%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.16%
EPS Next Y26.29%
EPS Next 2Y8.78%
EPS Next 3Y4.57%
EPS Next 5Y5.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.83%
EBIT Next 3Y6.2%
EBIT Next 5Y4.27%
FCF growth 1Y-177.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-179.49%
OCF growth 3YN/A
OCF growth 5YN/A

SILVERBACK THERAPEUTICS INC / SBTX Fundamental Analysis FAQ

What is the fundamental rating for SBTX stock?

ChartMill assigns a fundamental rating of 4 / 10 to SBTX.


What is the valuation status of SILVERBACK THERAPEUTICS INC (SBTX) stock?

ChartMill assigns a valuation rating of 2 / 10 to SILVERBACK THERAPEUTICS INC (SBTX). This can be considered as Overvalued.


What is the profitability of SBTX stock?

SILVERBACK THERAPEUTICS INC (SBTX) has a profitability rating of 3 / 10.


What is the financial health of SILVERBACK THERAPEUTICS INC (SBTX) stock?

The financial health rating of SILVERBACK THERAPEUTICS INC (SBTX) is 8 / 10.